Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters

Andolina, 2012, How I treat childhood CML, Blood, 119, 1821, 10.1182/blood-2011-10-380774 Narayanan, 2013, Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis, Pediatr Blood Cancer, 60, 1148, 10.1002/pbc.24397 Shima, 2011, Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia, J Pediatr, 159, 676, 10.1016/j.jpeds.2011.03.046 Jaeger, 2012, Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment, Med Sci Monit, 18, Cr721, 10.12659/MSM.883599 Choeyprasert, 2017, Adverse effects of imatinib in children with chronic myelogenous leukemia, Pediatr Int, 59, 286, 10.1111/ped.13136 Neul, 2016, Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors, Trends Pharmacol Sci, 37, 904, 10.1016/j.tips.2016.08.003 Gong, 2017, PharmGKB summary: sorafenib pathways, Pharmacogenet Genomics, 27, 240, 10.1097/FPC.0000000000000279 Mehlig, 2015, Inhibitory effects of imatinib on vitamin D₃ synthesis in human keratinocytes, Mol Med Rep, 11, 3143, 10.3892/mmr.2014.3074 Bikle, 2014, Vitamin D metabolism, mechanism of action, and clinical applications, Chem Biol, 21, 319, 10.1016/j.chembiol.2013.12.016 Thomas, 2004, Active transport of imatinib into and out of cells: implications for drug resistance, Blood, 104, 3739, 10.1182/blood-2003-12-4276 Hu, 2008, Interaction of imatinib with human organic ion carriers, Clin Cancer Res, 14, 3141, 10.1158/1078-0432.CCR-07-4913 Fan, 2009, Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer, J Pharmacol Exp Ther, 330, 389, 10.1124/jpet.108.149815 Mondul, 2017, Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges, Epidemiol Rev, 39, 28, 10.1093/epirev/mxx005 Wang, 2015, Serum 25-Hydroxyvitamin D Levels and Prognosis in Hematological Malignancies: A Systematic Review and Meta-Analysis, Cellular Physiology and Biochemistry, 35, 1999, 10.1159/000374007 Kulling, 2017, Vitamin D in hematological disorders and malignancies, European Journal of Haematology, 98, 187, 10.1111/ejh.12818 Radujkovic, 2017, Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia, Clinical Nutrition, 36, 542, 10.1016/j.clnu.2016.01.021 Łuczyńska, 2013, Plasma 25-hydroxyvitamin D concentration and lymphoma risk: results of the European Prospective Investigation into Cancer and Nutrition, Am J Clin Nutr, 98, 827, 10.3945/ajcn.112.054676 Fakih, 2009, Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer, International journal of colorectal disease, 24, 219, 10.1007/s00384-008-0593-y Thomas, 2011, Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies, Hematology, 16, 278, 10.1179/102453311X13085644679908 Omran, 2020, Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients, Frontiers in Oncology, 10 Baccarani, 2013, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, Blood, 122, 872, 10.1182/blood-2013-05-501569 Holick, 2011, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 96, 1911, 10.1210/jc.2011-0385 Elkerdany, 2014, Serum 25-hydroxyvitamin D levels in relation to disease status and prognosis in acute myeloid leukemia, The Egyptian Journal of Haematology, 39, 47, 10.4103/1110-1067.139757 Lee, 2014, Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia, Cancer, 120, 521, 10.1002/cncr.28368 Wang, 2015, Serum 25-hydroxyvitamin D levels and prognosis in hematological malignancies: a systematic review and meta-analysis, Cell Physiol Biochem, 35, 1999, 10.1159/000374007 Genc, 2013, Vitamin D in childhood cancer: a promising anticancer agent?, Pediatr Endocrinol Rev, 10, 485 Gao, 2018, Hepatic Transport of 25-Hydroxyvitamin D(3) Conjugates: A Mechanism of 25-Hydroxyvitamin D(3) Delivery to the Intestinal Tract, Drug Metab Dispos, 46, 581, 10.1124/dmd.117.078881 Maj, 2015, Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model, International journal of molecular sciences, 16, 27191, 10.3390/ijms161126016 Campiotti, 2018, Vitamin D and tyrosine kinase inhibitors in chronic myeloid leukemia, Internal and Emergency Medicine, 13, 1337, 10.1007/s11739-018-1957-0 Garland, 2006, The role of vitamin D in cancer prevention, Am J Public Health, 96, 252, 10.2105/AJPH.2004.045260 Robsahm, 2004, Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway), Cancer Causes Control, 15, 149, 10.1023/B:CACO.0000019494.34403.09 Zhou, 2007, Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients, J Clin Oncol, 25, 479, 10.1200/JCO.2006.07.5358 Giovannucci, 2006, Prospective study of predictors of vitamin D status and cancer incidence and mortality in men, J Natl Cancer Inst, 98, 451, 10.1093/jnci/djj101 Gorham, 2005, Vitamin D and prevention of colorectal cancer, J Steroid Biochem Mol Biol, 97, 179, 10.1016/j.jsbmb.2005.06.018 Ahonen, 2000, Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland), Cancer Causes Control, 11, 847, 10.1023/A:1008923802001 Freedman, 2007, Prospective study of serum vitamin D and cancer mortality in the United States, J Natl Cancer Inst, 99, 1594, 10.1093/jnci/djm204 Tangpricha, 2004, Prevalence of vitamin D deficiency in patients attending an outpatient cancer care clinic in Boston, Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 10, 292, 10.4158/EP.10.3.292 Abe, 1981, Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3, Proc Natl Acad Sci U S A,, 78, 4990, 10.1073/pnas.78.8.4990 Honma, 1983, 1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells, Proc Natl Acad Sci U S A,, 80, 201, 10.1073/pnas.80.1.201 Deeb, 2007, Vitamin D signalling pathways in cancer: potential for anticancer therapeutics, Nat Rev Cancer, 7, 684, 10.1038/nrc2196 Dunlap, 2003, 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells, British journal of cancer, 89, 746, 10.1038/sj.bjc.6601161 Politzer, 2005, Long-term clinical remission of chronic lymphocytic leukaemia by dietary means, S Afr Med J, 95, 321